Cytokinetics (MIL:1CYTK) Cyclically Adjusted FCF per Share: €-2.55 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1CYTK Cytokinetics Inc MIL:1CYTK
30 GF Score
Price €59.06
GF Value €200.97
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cytokinetics Cyclically Adjusted FCF per Share?

Cytokinetics MIL:1CYTK 30 Cyclically Adjusted FCF per Share is €-2.55 as of Jun. 2026. GuruFocus rates MIL:1CYTK with a GF Score™ of 30/100 and a GF Value™ of €200.97 (Possible Value Trap). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Cytokinetics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-1.075. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2.55 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -22.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -15.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Cytokinetics was 34.10% per year. The lowest was -22.90% per year. And the median was 8.70% per year.

As of today (2026-09-22), Cytokinetics's current stock price is €59.06. Cytokinetics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-2.55. Cytokinetics's Cyclically Adjusted Price-to-FCF of today is .


Cytokinetics  (MIL:1CYTK) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Cytokinetics Cyclically Adjusted FCF per Share Related Terms


Cytokinetics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Cytokinetics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytokinetics Cyclically Adjusted FCF per Share Chart

Cytokinetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.98 -1.19 -1.59 -1.84 -2.30

Cytokinetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.23 -2.29 -2.36 -2.45 -2.55

MIL:1CYTK vs IONS, APGE, KYMR: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Cytokinetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Cyclically Adjusted Price-to-FCF falls into.


MIL:1CYTK
30GF Score
Cytokinetics Inc MIL:1CYTK
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytokinetics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cytokinetics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.075/333.9520*333.9520
=-1.075

Current CPI (Jun. 2026) = 333.9520.

Cytokinetics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.265 241.428 -0.367
201612 1.604 241.432 2.219
201703 -0.504 243.801 -0.690
201706 -0.580 244.955 -0.791
201709 -0.354 246.819 -0.479
201712 -0.387 246.524 -0.524
201803 -0.453 249.554 -0.606
201806 -0.430 251.989 -0.570
201809 -0.534 252.439 -0.706
201812 -0.228 251.233 -0.303
201903 -0.436 254.202 -0.573
201906 -0.386 256.143 -0.503
201909 -0.335 256.759 -0.436
201912 -0.316 256.974 -0.411
202003 -0.477 258.115 -0.617
202006 -0.431 257.797 -0.558
202009 0.193 260.280 0.248
202012 0.552 260.474 0.708
202103 -0.421 264.877 -0.531
202106 -0.443 271.696 -0.545
202109 -0.592 274.310 -0.721
202112 -0.691 278.802 -0.828
202203 -0.316 287.504 -0.367
202206 -1.016 296.311 -1.145
202209 -1.002 296.808 -1.127
202212 -1.024 296.797 -1.152
202303 -1.202 301.836 -1.330
202306 -1.159 305.109 -1.269
202309 -0.924 307.789 -1.003
202312 -0.733 306.746 -0.798
202403 -1.171 312.332 -1.252
202406 -0.870 314.175 -0.925
202409 -0.754 315.301 -0.799
202412 -0.607 315.605 -0.642
202503 -1.101 319.799 -1.150
202506 -0.900 322.561 -0.932
202509 -0.774 324.800 -0.796
202512 -1.052 324.054 -1.084
202603 -1.050 330.213 -1.062
202606 -1.075 333.952 -1.075

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-2.55 mean?
Cytokinetics (MIL:1CYTK) has a Cyclically Adjusted FCF per Share of €-2.55 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cytokinetics and its competitors.
Is Cytokinetics' Cyclically Adjusted FCF per Share too high?
Cytokinetics' current Cyclically Adjusted FCF per Share is €-2.55. Overall, Cytokinetics has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cytokinetics' Cyclically Adjusted FCF per Share compare to IONS and APGE?
Cytokinetics' Cyclically Adjusted FCF per Share of €-2.55 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cytokinetics and its competitors. Cytokinetics's current Cyclically Adjusted FCF per Share is €-2.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytokinetics stock overvalued right now?
Based on GuruFocus' analysis, Cytokinetics (MIL:1CYTK) is currently considered Possible Value Trap. The stock's GF Value™ is €200.97, compared to a current price of €59.06 — trading 70.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-2.55. Cytokinetics' overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Cytokinetics (MIL:1CYTK), the current Cyclically Adjusted FCF per Share is €-2.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytokinetics (MIL:1CYTK) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of €59.06 is trading 70.6% below its estimated GF Value™ of €200.97. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for MIL:1CYTK:

  • Cyclically Adjusted FCF per Share: €-2.55
  • GF Value™: €200.97 vs. price of €59.06 (70.6% below fair value)
  • GF Score™: 30/100 with 7 warning signs

No single metric tells the full story. See the MIL:1CYTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cytokinetics Business Description

Other Exchanges CYTK:USAKK3A:Germany
Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
30GF Score

Get the complete analysis for MIL:1CYTK

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€59.06
Price
€200.97
GF Value